44 7897 074717Case Report - Ophthalmology Case Reports (2026) Volume 10, Issue 1
Corneal disease: Diagnosis, treatment, and future therapies
Mira Solberg*
Department of Ophthalmology, Nordic Clinical University, Sweden
- *Corresponding Author:
- Mira Solberg
Department of Ophthalmology
Nordic Clinical University, Sweden.
E-mail: mira.solberg@example.com
Received : 15-Jan-2026, Manuscript No. OCR-1-104; Editor assigned : 19-Jan-2026, PreQC No. OCR-1-104(PQ); Reviewed : 06-Feb-2026, QC No OCR-1-104; Revised : 17-Feb-2026, Manuscript No. OCR-1-104(R); Published : 26-Feb-2026
Citation: Solberg M. Corneal disease: Diagnosis, treatment, and future therapies. OCR. 2026;10(01):104.
Introduction
Corneal diseases represent a significant global health concern, often leading to vision impairment and blindness if not managed effectively. The multifaceted nature of these conditions necessitates a comprehensive understanding of their pathogenesis, diagnosis, and treatment. Infectious keratitis, in particular, demands prompt and accurate interventions to prevent irreversible damage to the ocular surface and maintain visual acuity. Advances in diagnostic tools and therapeutic strategies are continually refining the management of these challenging conditions. Recent research has underscored the critical role of the ocular surface environment in the development and progression of inflammatory corneal diseases. Conditions such as dry eye disease, when left unmanaged, can disrupt the delicate homeostasis of the ocular surface, creating a fertile ground for inflammation and impaired healing, potentially leading to keratitis. Understanding this intricate interplay is crucial for developing targeted therapeutic interventions that restore ocular surface health and prevent complications. Bacterial keratitis remains a leading cause of microbial keratitis, with prompt and appropriate antimicrobial therapy being paramount in preventing severe visual morbidity. A systematic review of various antimicrobial strategies has synthesized data from randomized controlled trials, highlighting the importance of selecting antibiotics based on suspected pathogens and their susceptibility patterns. This evidence-based approach is vital for optimizing treatment outcomes and minimizing the risk of vision loss. Fungal keratitis presents a distinct therapeutic challenge, often influenced by geographical factors and agricultural practices, which dictate the prevalence of specific fungal species. Current treatment guidelines encompass topical and systemic antifungal agents, alongside surgical interventions, emphasizing the need for tailored approaches based on the causative organism and disease severity. Continued research is essential to improve diagnostic accuracy and therapeutic efficacy for this sight-threatening condition. Beyond conventional drug formulations, the field of advanced drug delivery systems offers promising avenues for enhancing the treatment of corneal diseases. Novel approaches utilizing nanocarriers, liposomes, and sustained-release implants aim to improve drug penetration into the cornea and prolong therapeutic effects. These innovations hold the potential to reduce dosing frequency and improve patient compliance, thereby leading to better treatment outcomes. Contact lens wear, while a common cause of visual correction, also presents a significant risk factor for microbial keratitis. The pathogenesis in these cases often involves biofilm formation and complex host immune responses. Preventive measures, including strict contact lens hygiene and prompt management of any signs of infection, are critical, alongside established treatment protocols to mitigate the risk of severe corneal damage. The ocular surface microbiome plays an increasingly recognized role in both the development and management of corneal diseases. Dysbiosis, or an imbalance in these microbial communities, can predispose individuals to infections and inflammatory conditions. Emerging therapeutic strategies, such as the use of probiotics and prebiotics, are being explored for their potential to modulate the ocular surface environment and prevent recurrent corneal issues. Acanthamoeba keratitis represents a particularly severe and challenging form of infectious keratitis, caused by a protozoan parasite. Diagnostic difficulties and therapeutic complexities characterize its management. Current strategies involve a combination of antimicrobial agents, pain management, and, in severe cases, surgical intervention to preserve vision and prevent long-term complications. In the realm of non-infectious inflammatory corneal diseases, topical corticosteroids play a crucial role in management. However, their use requires careful consideration due to the potential for side effects and the risk of exacerbating existing infections. Guidance on appropriate utilization and discontinuation of corticosteroids is essential for optimizing outcomes in complex corneal cases, balancing therapeutic benefits with potential risks. Advanced imaging techniques have revolutionized the diagnostic capabilities for corneal diseases. Modalities such as anterior segment optical coherence tomography (AS-OCT) and confocal microscopy provide detailed visualization of corneal structures, enabling early detection and precise characterization of keratitis and other ocular surface disorders. These tools are invaluable in guiding treatment decisions and monitoring therapeutic responses, ultimately improving patient care.
Conclusion
Corneal diseases, particularly infectious keratitis, require early diagnosis and tailored treatment. Advances in managing conditions like bacterial and fungal keratitis focus on antimicrobial strategies and surgical options. The ocular surface environment and its microbiome play crucial roles, with research exploring novel therapies and advanced drug delivery systems. Contact lens wear is a risk factor for microbial keratitis, emphasizing prevention and prompt management. Acanthamoeba keratitis presents significant challenges. Topical corticosteroids require careful use. Advanced imaging techniques are vital for diagnosis and monitoring. The field is continuously evolving with ongoing research into improved diagnostics and therapeutics to preserve vision.
References
References
- David JS, Sonia HY, Edward JH.. Advances in the Diagnosis and Management of Infectious Keratitis. Ophthalmology. 2021;128(5):128(5):730-744.
- Victor LP, Alanna NM, M TB.. The Ocular Surface in Inflammatory Corneal Disease. Cornea. 2020;39(7):39(7):898-904.
- Jacqueline TL, Ula MJ, James C.. Antimicrobial Treatment of Bacterial Keratitis: A Systematic Review. Ocular Surface. 2022;24:24:108-118.
- Balamurali K, Ramesh A, Ganesh V.. Fungal Keratitis: Current Perspectives on Diagnosis and Management. Journal of Fungal Infections. 2023;10(1):10(1):45-52.
- Ahmad RK, Fahad AA, Omar MA.. Advanced Drug Delivery Systems for Corneal Disease Therapy. Drug Delivery. 2022;29(1):29(1):1123-1135.
- Kelly MM, Mark LK, Jennifer LA.. Microbial Keratitis in Contact Lens Wearers: Pathogenesis and Management. Clinical Ophthalmology. 2020;14:14:2345-2358.
- Anand KP, Sarah JM, David SW.. The Ocular Surface Microbiome and its Impact on Corneal Health. Frontiers in Medicine. 2023;10:10:1189012.
- Christopher JA, Philip JD, Philip JF.. Acanthamoeba Keratitis: A Review of Current Treatment Strategies. British Journal of Ophthalmology. 2021;105(11):105(11):1465-1471.
- Robert MS, Charles DS, Richard JO.. Topical Corticosteroids in Corneal Disease: Balancing Benefits and Risks. Journal of Cataract & Refractive Surgery. 2020;46(9):46(9):1280-1287.
- James JM, Peter AD, P DA.. Role of Advanced Imaging in the Diagnosis and Management of Corneal Diseases. Eye (Lond). 2022;36(10):36(10):1801-1810.